Home > Insider Trading > Filing (0000950170-25-076523)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1488039	Atossa Therapeutics Inc.	ATOS	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1008227	C Steven Quay	C/O Atossa Therapeutics, Inc., 10202 5Th Ave Ne, Suite 200 Seattle WA 98125	President & Ceo	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2025-05-21	11,239	$0.88	13,898	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	22,254	Indirect	By Ensisheim Partners, LLC

Footnotes

The price reported represents the weighted average purchase price per share. The shares were purchased in multiple transactions at prices ranging from $0.8794 to $0.9100. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of share purchased at each separate price.
Ensisheim Partners, LLC ("Ensisheim") is wholly owned by the Reporting Person and Dr. Shu-Chih Chen. The Reporting Person and Dr. Chen share voting and investment power over the securities held by Ensisheim. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.